4Q Revenues: $1.3 billion (+9%)
4Q Earnings: $300.2 million (+10%)
FY Revenues: $5.0 billion (+7%)
FY Earnings: $1.3 billion (+41%)
Comments: Tysabri revenues increased 11% in the quarter to $269 million. Global in-market sales were $380 million, up 14%. Avonex revenues were up 8% in the quarter to $703 million. Rituxan revenues from the company’s joint business arrangement were flat at $258 million in the quarter. For the year Tysabri revenues were up 20% to $1.1 billion with global in-market sales of $1.5 billion, up 23%. Avonex revenues were up 7% for the year to $2.7 billion. Rituxan sales were $1.0 billion for the year, down 7% due certain royalties from individual countries expiring and a charge of approximately $50 million related to Genentech’s arbitration with Hoechst GmbH.